The role of RNA modification in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a highly mortal type of primary liver cancer. Abnormal epigenetic modifications are present in HCC, and RNA modification is dynamic and reversible and is a key post-transcriptional regulator. With the in-depth study of post-transcriptional modifications, RNA modific...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Qiang, Wang, Dongxu, Xue, Tianyi, Lin, Chao, Gao, Yongjian, Sun, Liqun, Jin, Ye, Liu, Dianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479111/
https://www.ncbi.nlm.nih.gov/pubmed/36120301
http://dx.doi.org/10.3389/fphar.2022.984453
_version_ 1784790718124916736
author Feng, Qiang
Wang, Dongxu
Xue, Tianyi
Lin, Chao
Gao, Yongjian
Sun, Liqun
Jin, Ye
Liu, Dianfeng
author_facet Feng, Qiang
Wang, Dongxu
Xue, Tianyi
Lin, Chao
Gao, Yongjian
Sun, Liqun
Jin, Ye
Liu, Dianfeng
author_sort Feng, Qiang
collection PubMed
description Hepatocellular carcinoma (HCC) is a highly mortal type of primary liver cancer. Abnormal epigenetic modifications are present in HCC, and RNA modification is dynamic and reversible and is a key post-transcriptional regulator. With the in-depth study of post-transcriptional modifications, RNA modifications are aberrantly expressed in human cancers. Moreover, the regulators of RNA modifications can be used as potential targets for cancer therapy. In RNA modifications, N6-methyladenosine (m6A), N7-methylguanosine (m7G), and 5-methylcytosine (m5C) and their regulators have important regulatory roles in HCC progression and represent potential novel biomarkers for the confirmation of diagnosis and treatment of HCC. This review focuses on RNA modifications in HCC and the roles and mechanisms of m6A, m7G, m5C, N1-methyladenosine (m1A), N3-methylcytosine (m3C), and pseudouridine (ψ) on its development and maintenance. The potential therapeutic strategies of RNA modifications are elaborated for HCC.
format Online
Article
Text
id pubmed-9479111
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94791112022-09-17 The role of RNA modification in hepatocellular carcinoma Feng, Qiang Wang, Dongxu Xue, Tianyi Lin, Chao Gao, Yongjian Sun, Liqun Jin, Ye Liu, Dianfeng Front Pharmacol Pharmacology Hepatocellular carcinoma (HCC) is a highly mortal type of primary liver cancer. Abnormal epigenetic modifications are present in HCC, and RNA modification is dynamic and reversible and is a key post-transcriptional regulator. With the in-depth study of post-transcriptional modifications, RNA modifications are aberrantly expressed in human cancers. Moreover, the regulators of RNA modifications can be used as potential targets for cancer therapy. In RNA modifications, N6-methyladenosine (m6A), N7-methylguanosine (m7G), and 5-methylcytosine (m5C) and their regulators have important regulatory roles in HCC progression and represent potential novel biomarkers for the confirmation of diagnosis and treatment of HCC. This review focuses on RNA modifications in HCC and the roles and mechanisms of m6A, m7G, m5C, N1-methyladenosine (m1A), N3-methylcytosine (m3C), and pseudouridine (ψ) on its development and maintenance. The potential therapeutic strategies of RNA modifications are elaborated for HCC. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9479111/ /pubmed/36120301 http://dx.doi.org/10.3389/fphar.2022.984453 Text en Copyright © 2022 Feng, Wang, Xue, Lin, Gao, Sun, Jin and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Feng, Qiang
Wang, Dongxu
Xue, Tianyi
Lin, Chao
Gao, Yongjian
Sun, Liqun
Jin, Ye
Liu, Dianfeng
The role of RNA modification in hepatocellular carcinoma
title The role of RNA modification in hepatocellular carcinoma
title_full The role of RNA modification in hepatocellular carcinoma
title_fullStr The role of RNA modification in hepatocellular carcinoma
title_full_unstemmed The role of RNA modification in hepatocellular carcinoma
title_short The role of RNA modification in hepatocellular carcinoma
title_sort role of rna modification in hepatocellular carcinoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479111/
https://www.ncbi.nlm.nih.gov/pubmed/36120301
http://dx.doi.org/10.3389/fphar.2022.984453
work_keys_str_mv AT fengqiang theroleofrnamodificationinhepatocellularcarcinoma
AT wangdongxu theroleofrnamodificationinhepatocellularcarcinoma
AT xuetianyi theroleofrnamodificationinhepatocellularcarcinoma
AT linchao theroleofrnamodificationinhepatocellularcarcinoma
AT gaoyongjian theroleofrnamodificationinhepatocellularcarcinoma
AT sunliqun theroleofrnamodificationinhepatocellularcarcinoma
AT jinye theroleofrnamodificationinhepatocellularcarcinoma
AT liudianfeng theroleofrnamodificationinhepatocellularcarcinoma
AT fengqiang roleofrnamodificationinhepatocellularcarcinoma
AT wangdongxu roleofrnamodificationinhepatocellularcarcinoma
AT xuetianyi roleofrnamodificationinhepatocellularcarcinoma
AT linchao roleofrnamodificationinhepatocellularcarcinoma
AT gaoyongjian roleofrnamodificationinhepatocellularcarcinoma
AT sunliqun roleofrnamodificationinhepatocellularcarcinoma
AT jinye roleofrnamodificationinhepatocellularcarcinoma
AT liudianfeng roleofrnamodificationinhepatocellularcarcinoma

Ejemplares similares